- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06801223
En undersøgelse til vurdering af sulbactam-durlobactam hos pædiatriske patienter med Acinetobacter baumannii-calcoaceticus kompleks infektion
Et multicenter, open-label, fase 1B-undersøgelse for at vurdere farmakokinetikken, sikkerhed og tolerabilitet af sulbactam-durlobactam hos indlagte pædiatriske patienter fra fødslen
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections
Studieoversigt
Status
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: ISTX Clinical Trials
- Telefonnummer: 617-715-3600
- E-mail: Clinicaltrials@istx.com
Studiesteder
-
-
California
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- UCLA Medical Center
-
San Diego, California, Forenede Stater, 92123
- Rekruttering
- Rady Children's Hospital
-
-
North Carolina
-
Greenville, North Carolina, Forenede Stater, 27834
- Rekruttering
- ECU Brody School of Medicine
-
-
Texas
-
Galveston, Texas, Forenede Stater, 77555-5302
- Rekruttering
- University of Texas Medical Branch at Galveston
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patient from birth (defined as post-natal age of 7 days) to <18 years of age at the time of written informed consent (and assent, if applicable) and is hospitalized.
- Patient and/or parent(s) or legal guardian(s) have provided the written informed consent and/or assent.
- Patient has confirmed or suspected diagnosis of ABC infection and requires IV antibiotics for treatment.
- Patient has expected survival of 30 days after enrollment in the study.
- If patient is an individual of childbearing potential or reproductive potential, then the patient must remain abstinent OR must utilize one of the highly effective methods of contraception (ie, condom, combined oral contraceptive, implant, or injectable) from at least 30 days prior to screening until at least 30 days after administration of the last dose of study drug.
Exclusion Criteria:
-
Patient is a preterm infant, born at <28 weeks gestational age.
-
Patient has history of significant hypersensitivity or allergic reaction to any β-lactam, any contraindication to the excipients used in the formulation, or any contraindication to the use of β-lactam antibiotics. Note: For β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment.
-
Patient is in refractory septic shock at the time of enrollment, defined as persistent hypotension despite adequate fluid resuscitation or vasopressive therapy.
-
Patient is pregnant, breastfeeding, or intends to become pregnant.
-
Patient is receiving peritoneal dialysis or cardiopulmonary bypass.
-
Patient has received blood transfusion within 24 hours of study drug administration.
-
Patient is a newborn with clinically significant anemia who, in the opinion of the investigator, will not be able to tolerate the necessary blood draws to complete the study activities.
-
Patient (or patient's mother, if the patient is being breastfed) is using or will need to use any medications known to inhibit organic anion transporter 1 (OAT1) (eg, probenecid).
-
Patient has clinically significant renal, hepatic, or hemodynamic instability.
-
For Cohorts 1 through 3 only: patient has weight outside of the 5th to 95th percentile based on age.
-
Patient has an age-appropriate estimated creatinine clearance that indicates renal impairment.
-
Patient has the following laboratory results at Screening:
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3×upper limit of normal (ULN) and,
- Total bilirubin >2×ULN for age with conjugated/direct bilirubin >20% of the total. Note: Patients with AST or ALT up to 5×ULN are eligible if these elevations are acute and are documented as being directly related to the infectious process being treated.
-
Patient has clinically significant abnormal laboratory test results not related to the underlying infection that might expose the patient to risk by participating in the trial, confound the results of the trial, or interfere with the patient's participation for the full duration of the trial.
-
Patient (or patient's mother, if the patient is being breastfed) has participated in a clinical study involving investigational medication or an investigational device within the last 30 days or 5 half-lives, whichever is longer, prior to first dose of the study drug.
-
Patient has any condition that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the data.
-
Patient is unable or unwilling, in the opinion of the investigator, to comply with the protocol.
-
Patient (or patient's mother, if the patient is being breastfed) has previously received durlobactam.
-
Patient (or patient's mother, if the patient is being breastfed) has received sulbactam and/or sulbactam-containing regimens (eg, Unasyn) within 72 hours of first dose of the study drug.
-
Patient (or patient's mother, if the patient is being breastfed) has received amphotericin B within 7 days of first dose of the study drug.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Cohort 1
Pediatric patients 12 years to <18 years of age Sulbactam 25mg/kg -Durlobactam 25mg/kg, not to exceed 1g sulbactam - 1g durlobactam (Every 6 hours) |
25mg/kg SUL and 25mg/kg DUR
Andre navne:
|
|
Eksperimentel: Cohort 2
Pediatric patients 6 years to <12 years of age Sulbactam 25mg/kg -Durlobactam 25mg/kg, not to exceed 1g sulbactam - 1g durlobactam (Every 6 hours) |
25mg/kg SUL and 25mg/kg DUR
Andre navne:
|
|
Eksperimentel: Cohort 3
Pediatric patients 1 year to <6 years of age |
25mg/kg SUL and 25mg/kg DUR
Andre navne:
|
|
Eksperimentel: Cohort 4
Pediatric patients 3 months to <1 year of age |
25mg/kg SUL and 25mg/kg DUR
Andre navne:
|
|
Eksperimentel: Cohort 5 Subgroup 1
Aged 2 months to <3 months, term and preterm (gestational age >28 weeks) Term infants will receive 25mg/kg SUL and 25mg/kg DUR Preterm infants will receive 20mg/kg SUL and 20mg/kg DUR |
25mg/kg SUL and 25mg/kg DUR
Andre navne:
20mg/kg SUL and 20mg/kg DUR
Andre navne:
|
|
Eksperimentel: Cohort 5 Subgroup 2
Aged birth to <2 months, term and preterm (gestational age >28 weeks and post-natal age >7 days) Term infants will receive 25mg/kg SUL and 25mg/kg DUR Preterm infants will receive 20mg/kg SUL and 20mg/kg DUR |
25mg/kg SUL and 25mg/kg DUR
Andre navne:
20mg/kg SUL and 20mg/kg DUR
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Vurder de farmakokinetiske (PK) -parametre for maksimal koncentration (Cmax) af sulbactam og durlobactam
Tidsramme: Dag 1 og dag 3
|
Dag 1 og dag 3
|
|
Vurder PK-parametrene for område under plasmakoncentrationstidskurven fra 0 til 24 timer (AUC 0-24) af Sulbactam og Durlobactam
Tidsramme: Dag 1 og dag 3
|
Dag 1 og dag 3
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Forekomst af alvorlige TEAE'er
Tidsramme: 28 dage
|
28 dage
|
|
|
Procentdel af TEAE'er, der fører til undersøgelser af lægemiddel
Tidsramme: 28 dage
|
28 dage
|
|
|
Forekomst af relaterede tees
Tidsramme: 28 dage
|
28 dage
|
|
|
Ændring fra basisværdier for leverfunktion målt ved et omfattende metabolisk panel (CMP)
Tidsramme: Baseline og dag 28
|
Baseline og dag 28
|
|
|
Ændring fra basisværdier for nyrefunktion målt ved CMP
Tidsramme: Baseline og dag 28
|
Baseline og dag 28
|
|
|
Ændring fra baselineværdier af hæmoglobin
Tidsramme: Baseline og dag 28
|
Baseline og dag 28
|
|
|
Ændring fra baselineværdien af hvide blodlegemer
Tidsramme: Baseline og dag 28
|
Baseline og dag 28
|
|
|
Ændring fra baselineværdien af blodplader
Tidsramme: Baseline og dag 28
|
Baseline og dag 28
|
|
|
Ændring fra baselineværdien af diastolisk blodtryk
Tidsramme: Baseline og dag 28
|
Baseline og dag 28
|
|
|
Ændring fra baselineværdien af systolisk blodtryk
Tidsramme: Baseline og dag 28
|
Baseline og dag 28
|
|
|
Ændring fra baselineværdier af hjerterytme
Tidsramme: Baseline og dag 28
|
Baseline og dag 28
|
|
|
Ændring fra baselineværdien af respirationshastighed
Tidsramme: Baseline gennem dag 28
|
Baseline gennem dag 28
|
|
|
Ændring fra baseline -værdien af temperaturen
Tidsramme: Baseline og dag 28
|
Baseline og dag 28
|
|
|
Percentage of participants experiencing Treatment Emergent Adverse Events (TEAEs)
Tidsramme: 28 days
|
Defined as any adverse event occurring after exposure to the study drug or any AE that worsens in intensity or frequency |
28 days
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CS2514-2023-002
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-delingstidsramme
Data requests may be submitted starting 6 months after primary article publication and the data will be made accessible for up to 24 months; extensions may be considered on a case-by-case basis. Access criteria: Subject to certain criteria, conditions, and exceptions and upon completion of the review
IPD-delingsadgangskriterier
Subject to certain criteria, conditions, and exceptions and upon completion of the review and approval of the Research Proposal and Statistical Analysis Plan, Qualified Researchers engaging in independent scientific research can be provided de-identified IPD following the execution of a Data Sharing Agreement
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .